Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.41 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985089 | 0.92 | KDM4E (0.42) | GRM5PDE2AP2RX7MAPK14 | |
| SCHEMBL4982536 | 0.90 | P2RX7 (0.39) | PDE2AP2RX7MAPK14 | |
| SCHEMBL4986225 | 0.87 | GRM5 (0.46) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL4982974 | 0.85 | GRM5 (0.45) | GRM5KCNH2 | |
| SCHEMBL4984810 | 0.84 | KMT2A (0.43) | GRM5PDE2A | |
| SCHEMBL4989744 | 0.83 | ALDH1A1 (0.51) | PARP1GRM5KCNH2 | |
| SCHEMBL4988635 | 0.82 | EPHX2 (0.39) | — | |
| SCHEMBL4989344 | 0.82 | LMNA (0.43) | GRM5HCRTR1HCRTR2MAPK14 | |
| SCHEMBL4988879 | 0.81 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL4982578 | 0.79 | HTT (0.50) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | PARP1 1754/4885GRM5 231/4885HDAC8 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.